KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Operating Expenses (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Operating Expenses for 11 consecutive years, with $68.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 43.42% to $68.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $222.0 million through Dec 2025, up 22.55% year-over-year, with the annual reading at $222.0 million for FY2025, 22.55% up from the prior year.
  • Operating Expenses hit $68.8 million in Q4 2025 for Fulgent Genetics, up from $50.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $176.4 million in Q4 2023 to a low of $18.4 million in Q1 2021.
  • Historically, Operating Expenses has averaged $49.6 million across 5 years, with a median of $44.6 million in 2024.
  • Biggest five-year swings in Operating Expenses: skyrocketed 255.98% in 2023 and later crashed 72.79% in 2024.
  • Year by year, Operating Expenses stood at $38.7 million in 2021, then rose by 28.08% to $49.5 million in 2022, then surged by 255.98% to $176.4 million in 2023, then tumbled by 72.79% to $48.0 million in 2024, then skyrocketed by 43.42% to $68.8 million in 2025.
  • Business Quant data shows Operating Expenses for FLGT at $68.8 million in Q4 2025, $50.9 million in Q3 2025, and $54.1 million in Q2 2025.